Key Points AbbVie and Johnson & Johnson have resilient, noncyclical businesses. They are also outstanding dividend payers. 10 stocks we like better than AbbVie › The technology sector is an excellent place to find high-growth stocks with promising prospects. However, it is a cyclical sector that doesn't perform as well when the economy tanks. It's critical for investors to diversify their tech holdings, perhaps by putting their money into more defensive industries that behave differently during dow ...

Core Insights - Johnson & Johnson (JNJ) has signed a significant agreement with the Trump administration to lower drug prices in the U.S. [1] - JNJ is part of a broader trend among large-cap pharmaceutical companies committing to similar agreements to reduce drug prices [2] Agreement Details - Under the agreement, JNJ will reduce prescription drug prices to align with those in comparable developed countries, supporting the Most Favored Nation (MFN) pricing proposal [3] - JNJ will benefit from a limited-period exemption from import tariffs on pharmaceutical ingredients, contingent upon expanding its domestic manufacturing operations [4] Financial and Operational Impact - JNJ's shares have increased by 30.6% over the past six months, outperforming the industry growth of 20.4% [5] - The company is advancing a $55 billion plan to enhance U.S. manufacturing, research, and technology capabilities by early 2029 [6][7] - JNJ is constructing new facilities in Pennsylvania and North Carolina, including a $2 billion biologics plant expected to create approximately 5,000 jobs [8] Industry Trends - Other large-cap pharmaceutical companies are also investing significantly in U.S.-based manufacturing and R&D, with AstraZeneca committing $50 billion by 2030 and AbbVie planning over $10 billion by 2035 [9][10][13] - Lilly has announced a $27 billion investment to develop new manufacturing sites, enhancing production capacity for its marketed drugs [14]

Group 1 - Johnson & Johnson (JNJ) experienced a 0.5% decline in early trading on Friday [1][2] - The company agreed to lower prices on certain drugs and join the TrumpRx.gov platform in exchange for tariff exemptions and a U.S. investment plan [1][2] - Experts believe that the savings for most insured patients will be limited [1][2]

1. 1月9日(周五)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨004%，标普500指数期货涨0.11%，纳指期货涨0.20%。 | ■ US 30 | 49,283.30 | 49,354.80 | 49,215.70 | +17.60 | +0.04% | | --- | --- | --- | --- | --- | --- | | ■ US 500 | 6,929.00 | 6,932.30 | 6,913.00 | +7.60 | +0.11% | | ■ US Tech 100 | 25,559.30 | 25,585.70 | 25,446.70 | +52.20 | +0.20% | 2. 截至发稿，德国DAX指数涨0.41%，英国富时100指数涨0.52%，法国CAC40指数涨0.86%，欧洲斯托克50指数涨1.06%。 | I 德国DAX30 | 25,228.32 | 25,269.21 | 25,106.61 | +102.41 | +0.41% | | --- | --- | --- | --- | --- | --- | | 器 英国富时100 | 10,097.20 | ...

有统计数显示，美国患者们目前为处方药所支付的整体费用远高于其他发达国家，往往接近其他国家销 售价格的三倍。特朗普政府一直在施压制药商们把美国国内药价降至海外所支付的水平。 "这份联合协议满足了特朗普总统向美国制药行业提出的要求，并为公司的制药产品提供关税豁免，"强 生周四在一份声明中表示。不过双方协议的具体条款未予以披露，包括下调后的药价细节或涵盖哪些药 品。 美国制药巨头强生公司(JNJ.US)当地时间周四表示，已经与美国总统唐纳德·特朗普政府达成协议，将为 美国民众们下调药品价格，以换取获得特朗普政府至关重要的关税豁免。 据了解，在与强生达成协议之前，特朗普政府于2025年12月与另外九家美国大型制药公司达成协议，要 求它们下调面向联邦政府医疗补助计划(Medicaid)以及现金自费消费者们的药品价格，旨在使美国药品 成本与其他富裕发达国家的销售水平接轨。 强生表示，将参与特朗普政府推出的TrumpRx.gov网站，使美国人能够以大幅折扣价格购买其所需要的 强生公司药品。该公司还将以与其他发达国家相当的价格向Medicaid提供关键药品获取渠道。 根据12月达成的一项重磅协议，所有九家美国制药商同意下调其 ...

强生表示，将参与特朗普政府推出的TrumpRx.gov网站，使美国人能够以大幅折扣价格购买其所需要的 强生公司药品。该公司还将以与其他发达国家相当的价格向Medicaid提供关键药品获取渠道。 （原标题：?强生(JNJ.US)加入美国药品降价联盟 换取特朗普关税豁免） 智通财经APP获悉，美国制药巨头强生公司(JNJ.US)当地时间周四表示，已经与美国总统唐纳德·特朗普 政府达成协议，将为美国民众们下调药品价格，以换取获得特朗普政府至关重要的关税豁免。 据了解，在与强生达成协议之前，特朗普政府于2025年12月与另外九家美国大型制药公司达成协议，要 求它们下调面向联邦政府医疗补助计划(Medicaid)以及现金自费消费者们的药品价格，旨在使美国药品 成本与其他富裕发达国家的销售水平接轨。 有统计数显示，美国患者们目前为处方药所支付的整体费用远高于其他发达国家，往往接近其他国家销 售价格的三倍。特朗普政府一直在施压制药商们把美国国内药价降至海外所支付的水平。 "这份联合协议满足了特朗普总统向美国制药行业提出的要求，并为公司的制药产品提供关税豁免，"强 生周四在一份声明中表示。不过双方协议的具体条款未予以披露，包 ...

Group 1 - The Trump administration has reached a deal with Johnson & Johnson to lower the prices of certain medications, aiming to enhance affordability for consumers [1] - The agreement is part of a broader initiative to address prescription drug costs, which have been a significant concern for many Americans [1] - Johnson & Johnson is expected to implement price reductions on specific drugs, although the exact medications and the extent of the price cuts have not been detailed [1] Group 2 - This deal reflects ongoing efforts by the government to negotiate better pricing with pharmaceutical companies, which may influence future pricing strategies across the industry [1] - The collaboration with Johnson & Johnson could set a precedent for similar agreements with other pharmaceutical companies, potentially reshaping the competitive landscape [1] - The administration's focus on drug pricing is likely to impact public perception and trust in pharmaceutical companies, as affordability becomes a key issue for consumers [1]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

特朗普政府去年12月与其他九家主要制药公司达成协议，降低政府医疗补助计划和使用现金支付的消费 者的药品价格，旨在使美国的药品价格与其他富裕国家一致。 强生公司周四表示，已经与美国总统特朗普的政府达成协议，将降低美国人的药品价格，以换取美国的 关税豁免。 美国患者目前为处方药支付的费用要高得多，通常是其他发达国家的近三倍，特朗普一直在向制药商施 压，要求他们将价格降至国外支付的水平。 强生公司当地时间周四在一份声明中表示："该联合协议符合特朗普总统向行业提出的要求，并为公司 的制药产品提供了关税豁免。" 协议的具体条款没有披露，包括修订后药品价格的细节，以及涵盖哪些药品。 强生还表示，将加入TrumpRx.gov网站，让美国人以大幅折扣的价格购买其药品。此外，还将以与其他 发达国家相当的价格，为医疗补助计划（Medicaid）提供药品。 根据去年12月达成的协议，所有九家美国制药商都同意降低向低收入人群医疗补助计划（Medicaid）销 售的大部分药品的价格，承诺为常用药物节省"巨额费用"。 强生公司还表示，作为其去年宣布的550亿美元美国投资计划的一部分，将在北卡罗来纳州和宾夕法尼 亚州新建两家生产工厂。 强 ...

Core Viewpoint - Johnson & Johnson (JNJ.US) has reached an agreement with the Trump administration to lower drug prices in exchange for tariff exemptions, following similar agreements by other pharmaceutical companies [1] Group 1: Company Agreements - Johnson & Johnson is the latest pharmaceutical company to agree to lower drug prices, joining GlaxoSmithKline (GSK.US), Merck (MRK.US), and Novartis (NVS.US) [1] - Pfizer (PFE.US) and AstraZeneca (AZN.US) were among the first to agree to reduce prescription drug prices for tariff relief [1] - Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) also reached agreements to significantly lower prices for commonly used GLP-1 weight loss drugs for Medicare, Medicaid, and out-of-pocket patients [1]